Association of serum elabela levels with carotid artery stenosis in patients with non-cardioembolic ischemic stroke

References

• 1. Johnston SC, Mendis S, Mathers CD. Global variation in stroke burden and mortality: estimates from monitoring, surveillance, and modelling. Lancet Neurol. 8, 345–354 (2009).
  MedlineGoogle Scholar
• 2. Ay H, Benner T, Arsava EM et al. A computerized algorithm for etiologic classification of ischemic stroke: the causative classification of stroke system. Stroke 38, 2979–2984 (2007).
  MedlineGoogle Scholar
• 3. Linden B. National Institute for Health and Care Excellence NG128 stroke and transient ischaemic attack in over 16s: diagnosis and initial management. British J. Cardiac Nursing 15, 1–5 (2020).
  Google Scholar
• 4. Virmani R, Kolodgie FD, Burke AP et al. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 20, 1262–1275 (2000).
  Medline CASGoogle Scholar
• 5. Chng SC, Ho L, Tian J et al. Elabela: a hormone essential for heart development signals via the apelin receptor. Dev. Cell 27, 672–680 (2013).
  Medline CASGoogle Scholar
• 6. Yang P, Read C, Kuc RE et al. Elabela/toddler is an endogenous agonist of the apelin apj receptor in the adult cardiovascular system, and exogenous administration of the peptide compensates for the down-regulation of its expression in pulmonary arterial hypertension. Circulation 135, 1160–1173 (2017).
  Medline CASGoogle Scholar
• 7. Li C, Miao X, Wang S et al. Elabela may regulate SIRT3-mediated inhibition of oxidative stress through foxo3a deacetylation preventing diabetic-induced myocardial injury. J. Cell. Mol. Med. 25, 323–332 (2021).
  Medline CASGoogle Scholar
• 8. Wang X, Liang G, Guo Q et al. Elabela improves endothelial cell function via the ELA-APJ axis by activating the PI3K/Akt signalling pathway in HUVECs and EA.hy926 cells. Clin. Exp. Pharmacol. Physiol. 47, 1953–1964 (2020).
  Medline CASGoogle Scholar
• 9. Ma Z, Zhao L, Martin S et al. Lower plasma elabela levels in hypertensive patients with heart failure predict the occurrence of major adverse cardiac events: a preliminary study. Front Cardiovasc. Med. 8, 638468 (2021).
  Medline CASGoogle Scholar
• 10. DU SL, Yang XC, Zhong JC et al. Plasma levels of elabela are associated with coronary angiographic severity in patients with acute coronary syndrome. J. Geriatr. Cardiol. 17, 674–679 (2020).
  Medline CASGoogle Scholar
• 11. Kaplan M, Yavuz F, Kaplan GI, Bursa N, Vuruşkan E, Sucu M. Elabela as a novel marker: well-correlated with WIfI amputation risk score in lower extremity arterial disease patients. Anatol. J. Cardiol. 25, 330–337 (2021).
  Medline CASGoogle Scholar
• 12. Barnett HJM, Taylor DW, Haynes RB et al. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N. Engl. J. Med. 325, 445–453 (1991).
  Medline CASGoogle Scholar
• 13. Nakahashi T, Tada H, Sakata K et al. Additive prognostic value of carotid plaque score to enhance the age, creatinine, and ejection fraction score in patients with acute coronary syndrome. J. Atheroscler. Thromb. 25, 709–719 (2018).
  MedlineGoogle Scholar
• 14. Steinvil A, Sadeh B, Arbel Y et al. Prevalence and predictors of concomitant carotid and coronary artery atherosclerotic disease. J. Am. Coll. Cardiol. 57, 779–783 (2011).
  MedlineGoogle Scholar
• 15. Yuan C, Yip SP, Wu VW et al. Association between genetic polymorphisms and carotid atherosclerosis in patients treated with radiotherapy for nasopharyngeal carcinoma. Radiat. Oncol. 10, 39 (2015).
  MedlineGoogle Scholar
• 16. Tang W, Shen X, Li H et al. The independent and incremental value of ultrasound carotid plaque length to predict the presence and severity of coronary artery disease: analysis from the carotid plaque length prospective registry. Eur. Heart J. Cardiovasc. Imaging 21, 389–396 (2020).
  MedlineGoogle Scholar
• 17. Pitkin SL, Maguire JJ, Kuc RE et al. Modulation of the apelin/APJ system in heart failure and atherosclerosis in man. Br. J. Pharmacol. 160, 1785–1795 (2010).
  Medline CASGoogle Scholar
• 18. Kleinz MJ, Davenport AP. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul. Pept. 118, 119–125 (2004).
  Medline CASGoogle Scholar
• 19. Cox CM, D'Agostino SL, Miller MK et al. Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. Dev. Biol. 296, 177–189 (2006).
  Medline CASGoogle Scholar
• 20. Masoud AG, Lin J, Azad AK et al. Apelin directs endothelial cell differentiation and vascular repair following immune-mediated injury. J. Clin. Invest. 130, 94–107 (2020).
  Medline CASGoogle Scholar
• 21. Wang W, Shen M, Fischer C et al. Apelin protects against abdominal aortic aneurysm and the therapeutic role of neutral endopeptidase resistant apelin analogs. Proc. Natl Acad. Sci. USA 116, 13006–13015 (2019).
  Medline CASGoogle Scholar
• 22. Tang R, Wang R, Ao X et al. Plasma level of apelin and carotid atherosclerosis in maintenance hemodialysis patients. Chinese 42, 617–622 (2017).
  Google Scholar
• 23. Topsakal S, Akin F, Turgut S et al. Relationship of apelin, procalcitonin, and fetuin-A concentrations with carotid intima-media thickness in acromegaly. Ann. Clin. Biochem. 52, 456–461 (2015).
  Medline CASGoogle Scholar
• 24. Gunter S, Solomon A, Tsang L et al. Apelin concentrations are associated with altered atherosclerotic plaque stability mediator levels and atherosclerosis in rheumatoid arthritis. Atherosclerosis 256, 75–81 (2017).
  Medline CASGoogle Scholar
• 25. Zhou Y, Wang Y, Qiao S. Apelin: a potential marker of coronary artery stenosis and atherosclerotic plaque stability in ACS patients. Int. Heart J. 55, 204–212 (2014).
  Medline CASGoogle Scholar
• 26. Sabry RN, El Wakeel MA, El-Kassas GM et al. Serum apelin: a new marker of early atherosclerosis in children with type 1 diabetes mellitus. Open Access Maced. J. Med. Sci. 6, 613–617 (2018).
  MedlineGoogle Scholar
• 27. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler. Thromb. Vasc. Biol. 23, 168–175 (2003).
  Medline CASGoogle Scholar
• 28. Bokuda K, Morimoto S, Seki Y et al. Greater reductions in plasma aldosterone with aliskiren in hypertensive patients with higher soluble (pro)renin receptor level. Hypertens. Res. 41, 435–444 (2018).
  Medline CASGoogle Scholar
• 29. Xu C, Wang F, Chen Y et al. Elabela antagonizes intrarenal renin-angiotensin system to lower blood pressure and protects against renal injury. Am. J. Physiol. Renal Physiol. 318, 1122–1135 (2020).
  Google Scholar
• 30. Panaitescu B, Romero R, Gomez-Lopez N et al. Elabela plasma concentrations are increased in women with late-onset pre-eclampsia. J. Matern. Fetal Neonatal Med. 33, 5–15 (2020).
  Medline CASGoogle Scholar
• 31. Deng C, Chen H, Yang N et al. Apela Regulates Fluid Homeostasis by Binding to the APJ Receptor to Activate Gi Signaling. J. Biol. Chem. 290, 18261–18268 (2015).
  Medline CASGoogle Scholar
• 32. Rikitake Y. The apelin/APJ system in the regulation of vascular tone: friend or foe? J. Biochem. 169, 383–386 (2021).
  Medline CASGoogle Scholar
• 33. Cheng J, Luo X, Huang Z et al. Apelin/APJ system: a potential therapeutic target for endothelial dysfunction-related diseases. J. Cell. Physiol. 234, 12149–12160 (2019).
  Medline CASGoogle Scholar
• 34. Xu C. The elabela in hypertension, cardiovascular disease, renal disease, and pre-eclampsia: an update. J. Hypertens. 39, 12–22 (2021).
  Medline CASGoogle Scholar
• 35. Chong KS, Gardner RS, Ashley EA, Dargie HJ, McDonagh TA. Emerging role of the apelin system in cardiovascular homeostasis. Biomark. Med. 1, 37–43 (2007).
  CASGoogle Scholar